These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29544740)

  • 1. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma.
    Garnier M; Zaragoza J; Bénéton N; Bens G; Meurisse V; Samimi M; Maillard H; Machet L
    J Am Acad Dermatol; 2018 Jul; 79(1):165-167.e2. PubMed ID: 29544740
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
    Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
    JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.
    Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
    J Dermatol; 2018 Sep; 45(9):e250-e251. PubMed ID: 29572922
    [No Abstract]   [Full Text] [Related]  

  • 5. Gut microbiome and immunotherapy response.
    Burki TK
    Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
    Boussemart L; Johnson A; Schrock AB; Pal SK; Frampton GM; Fabrizio D; Chalmers Z; Lotem M; Gibney G; Russell J; Chmielowski B; Ross JS; Stephens PJ; Miller VA; Ali SM
    J Am Acad Dermatol; 2019 Jun; 80(6):1780-1782. PubMed ID: 30576761
    [No Abstract]   [Full Text] [Related]  

  • 7. Melanoma: is immunotherapy of benefit?
    Faries MB; Morton DL
    Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
    [No Abstract]   [Full Text] [Related]  

  • 8. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
    [No Abstract]   [Full Text] [Related]  

  • 10. A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study.
    Zaragoza J; Kervarrec T; Touzé A; Avenel-Audran M; Beneton N; Esteve E; Wierzbicka Hainaut E; Aubin F; Machet L; Samimi M
    J Am Acad Dermatol; 2016 Oct; 75(4):712-721.e1. PubMed ID: 27544490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma.
    Woodcock JL; Eyre ZW; Stoddard GJ; Callis Duffin K; Bowen AR
    J Am Acad Dermatol; 2017 Oct; 77(4):766-768. PubMed ID: 28917460
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
    Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
    Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
    Shah DJ; Dronca RS
    Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
    Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
    Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.